Company news

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A (SSE:600332) news

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A news releases on 6ix. Latest, Sep 22, 2026: "Guangzhou Baiyunshan Pharmaceutical Holdings…

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A (SSE:600332) news

Press releases & updates

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Indicative Announcement on Change in Equity Structure of Controlling Shareholder

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Changes to Matters Concerning the Equity Investment Fund and Progress of the Related Party Transaction

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Receipt of the Drug Registration Certificate in Macao by Guangzhou Baiyunshan Bioproducts Co., Ltd.

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Convening the 2026 Semi-annual Performance Briefing

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Implementation of Dividend Distribution for the First Half of 2026

WALOVI Launches Indonesia‑Classic and Global Cans at Global Investment & New Product Launch Conference in Jakarta

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Full Text of the Semi-annual Report for 2026

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subsidiary

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Receipt of Macao Drug Registration Certificate by Subsidiary

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Notice on Convening the 1st Extraordinary General Meeting in 2026

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Change of "Drug Manufacturing License" of Subsidiary

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on the Receipt of a Macao Drug Registration Certificate by a Branch

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Indicative Announcement on the Pre-Listing of the Capital Increase and Share Expansion of a Subsidiary

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Subsidiary's Drug Passing Generic Drug Consistency Evaluation

"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Completion of Legal Representative Change Registration and Renewal of Business License

"Corporate Value and Return Enhancement" Action Plan 2026

Announcement on Branch Receiving Drug Registration Certificate

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Completing Term Change of the Board of Directors and Appointing Senior Management Members

Announcement on Election of Employee Representative Director

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subsidiary

Announcement on Election of Board of Directors at Expiry of Term of Office

Announcement on Change of Subsidiary's Drug Production License

Announcement on Resolutions of the 34th Meeting of the 9th Board of Directors

Announcement on Recognition of Subsidiary as High-tech Enterprise

Announcement on Branch Receiving Pharmaceutical Registration Certificate in Macau

Special Report on Deposit, Management and Actual Use of Raised Funds in 2025

Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials

Announcement on Resignation of Vice Chairman

Announcement on Progress in Subsidiary’s Acquisition of 100% Equity of Zhejiang Pharmaceutical Industry Corp., Ltd.

Announcement on Progress in Guangzhou Guangyao Phase II Fund Equity Investment Partnership (Limited Partnership) Acquiring an 11.04% Equity Interest in Nanjing Pharmaceutical Company Limited

Announcement on Partial Drugs Being Selected for National Procurement Continuation After the Expiry of Agreement

Announcement on Branch Obtaining Drug Supplementary Application Approval

Announcement on Subsidiary's Drug Passing Generic Consistency Evaluation

Announcement on the Completion of Private Fund Filing for Guangzhou Guangyao Guangkai Venture Capital Investment Fund Partnership (Limited Partnership) and the Progress of the Related Party Transaction

Announcement on Progress in Affiliated Enterprises' Participation in Investing in the Establishment of Guangzhou Liwan Guangya Venture Capital Fund Partnership Enterprise (Limited Partnership) and Related Party Transactions

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Progress in Subsidiary’s Participation in the Investment and Establishment of Guangzhou Guangyao Guangkai Venture Capital Investment Fund Partnership (Limited Partnership) and Related Party Transactions

Announcement on Guangzhou Baiyunshan Bioproducts Co., Ltd. Receiving Drug Registration Certificate

Announcement on Estimated Daily Related Party Transactions in 2026

Announcement on Subsidiary’s Acquisition of 100% Equity of Zhejiang Pharmaceutical Industry Corp., Ltd.

Announcement on Cancellation of Subsidiary's Drug Production License

Notice on the 3rd Extraordinary General Meeting in 2025

Announcement on Closing Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital

Announcement on Land Expropriation Compensation for a Subsidiary

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Subsidiary Receiving Vietnamese Drug Registration Certificate